Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MP 1032

Next Previous
Drug Profile

MP 1032

Alternative Names: MP-1032

Latest Information Update: 07 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MetrioPharm
  • Class Amines; Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ketones; Phthalazines; Small molecules; Sodium compounds
  • Mechanism of Action Free radical scavengers; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; Plaque psoriasis
  • Phase I Duchenne muscular dystrophy; Infections; Inflammatory bowel diseases; Juvenile rheumatoid arthritis; Multiple sclerosis; Rheumatoid arthritis
  • No development reported Chronic obstructive pulmonary disease; Neurodegenerative disorders

Most Recent Events

  • 07 Aug 2024 Phase-I clinical trials in Infections (IV) (Metriopharm pipeline, August 2024)
  • 07 Aug 2024 Phase-I clinical trials in Infections (PO) (Metriopharm pipeline, August 2024)
  • 28 May 2024 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Switzerland (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top